HBIO — Harvard Bioscience Cashflow Statement
0.000.00%
Last trade - 00:00- $15.37m
- $48.22m
- $94.14m
Annual cashflow statement for Harvard Bioscience, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -7.81 | -0.288 | -9.52 | -3.42 | -12.4 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 5.55 | 4.45 | 0.791 | 5.51 | 6.26 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 4.11 | -10.2 | 2.72 | 4.6 | 0.065 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Accounts Payable | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 9.33 | 1.26 | 1.15 | 14 | 1.44 |
| Capital Expenditures | -1.15 | -1.34 | -1.59 | -2.31 | -3.26 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -0.25 | — | — | 0.512 | 1.92 |
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -1.4 | -1.34 | -1.59 | -1.8 | -1.34 |
| Financing Cash Flow Items | -2.37 | -3.62 | -1.63 | -2.52 | -0.738 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -7.97 | -0.252 | -2.84 | -12.1 | -0.131 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.018 | -0.496 | -3.31 | -0.225 | -0.175 |